생체이용률 향상 기술 및 서비스 시장 : 약제 유형별, BCS 분류별, 향상 접근별, 제형별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Bioavailability Enhancement Technologies and Services Market, By Drug Type, By BCS Classification, By Enhancement Approach, By Dosage Form, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

US $ 3,250 ￦ 4,590,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 4,650 ￦ 6,568,000

PDF (5 User License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,650 ￦ 7,980,000

PDF & Excel (Enterprise User License)

PDF & Excel 보고서를 동일 기업 내 모든 사용자가 사용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

리포트 하이라이트

생체이용률 향상 기술 및 서비스 시장 규모는 2023년에 21억 2,345만 달러에 달하며, 2024-2032년 CAGR 7.5%로 확대

생체이용률 향상 기술 및 서비스 시장 - 시장 역학

만성질환의 급증과 개발의 과제는 시장 성장을 가속합니다.

세계 만성질환의 급증과 의약품 개발의 어려움으로 인해 생체이용률 향상 기술 및 서비스 시장이 크게 성장하고 있습니다. 세계심장연맹(World Heart Federation)의 최근 추정에 따르면 전 세계 사망자 수의 약 1/3에 해당하는 2,050만 명 이상이 CVD로 사망하고 있습니다.

생체이용률 향상 기술은 약물의 흡수성, 용해도 및 효능을 향상시켜 이러한 복잡한 치료 요구에 대응하는 데 중요한 역할을 합니다. 제약사들은 규제 기준을 충족하고 만성질환 치료 옵션을 강화하기 위해 혁신적인 제형 기술 및 약물전달 시스템에 대한 투자를 늘리고 있으며, 이는 이 시장 부문의 확장을 주도하고 있습니다.

생체이용률 향상 기술 및 서비스 시장 - 주요 인사이트

AnalystView Market Insights의 리서치 애널리스트의 분석에 따르면 세계 시장은 예측 기간(2024-2032년) 동안 연평균 약 7.5%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.

약물 유형별로는 신약 승인이 22023년 가장 높은 시장 점유율을 차지했습니다.

BCS 분류 세분화에 따르면 2023년 BCS-II가 주요 유형이었습니다.

강화 접근 방식의 세분화에 따르면 2023년에는 고체 분산체가 주요 유형으로 나타났습니다.

제형별로는 2023년 액제가 주요 유형이었습니다.

지역별로는 북미가 2023년 매출에서 선두를 차지했습니다.

생체이용률 향상 기술 및 서비스 시장 - 세분화 분석 :

세계의 생체이용률 향상 기술 및 서비스 시장은 약물 유형, BCS 분류, 향상 접근법, 제형, 지역별로 세분화됩니다.

시장은 약물 유형에 따라 신약 승인과 제네릭 의약품의 두 가지로 분류됩니다. 생체이용률 향상 기술 및 서비스 분야의 신약 승인은 의약품 제제 및 전달 시스템에서 상당한 진전을 보이고 있습니다. 이러한 승인은 특히 생체이용률에 문제가 있는 의약품의 흡수성, 용해도 및 전반적인 효능을 개선하기 위한 혁신적인 접근법을 강조하는 경우가 많습니다. 주요 승인 동향으로는 나노기술, 지질 기반 제제, 방출 제어 시스템과 같은 새로운 제형 기술의 채택이 포함됩니다.

시장은 BCS 분류에 따라 BCS II 등급과 BCS IV 등급의 두 가지 범주로 나뉘며, BCS II 등급은 투과성이 높지만 용해도가 낮습니다. 이러한 약물의 생체이용률을 높이기 위해 입자 크기 감소, 고체 분산, 사이클로덱스트린 복합화, 지질 기반 제형 및 나노 기술과 같은 고급 제형 전략이 일반적으로 사용됩니다. 이러한 기술은 용해 속도를 개선하고 궁극적으로 흡수율을 높여 치료 효과를 보장하는 것을 목표로 합니다.

생체이용률 향상 기술 및 서비스 시장 - 지역적 인사이트

북미가 세계 의약품 생체이용률 향상 시장에서 우위를 점하고 있는 것은 탄탄한 제약 산업, 첨단인 규제 환경, 강력한 R&D 역량에 기인합니다. 이 지역에는 의약품의 흡수율과 효능을 향상시키는 혁신적인 기술을 개발하고 도입하는 데 전념하는 광범위한 조사 및 제조 인프라를 갖춘 대형 제약사들이 있습니다. 미국 FDA와 같은 규제기관은 생물학적 동등성 및 치료 효과 요건을 포함한 엄격한 의약품 승인 기준을 시행하고 있습니다. 이러한 규제 프레임워크는 엄격한 기준을 충족하고 컴플라이언스를 보장하기 위해 생체이용률 향상 기술에 대한 지속적인 혁신을 촉진하고, 이를 통해 시장 리더십을 주도하고 있습니다.

또한 북미는 학계와 연구기관이 업계 이해관계자들과 긴밀하게 협력하는 역동적인 생태계의 혜택을 누리고 있습니다. 이러한 협력은 새로운 약물전달 시스템, 제형 및 바이오의약품 개발을 촉진하고, 생체이용률 향상 전략을 발전시키는 데 기여하고 있습니다.

생체이용률 향상 기술 및 서비스 시장 - 경쟁 현황:

의약품의 생체이용률 향상 시장은 대기업부터 중소기업까지 치열한 경쟁을 벌이고 있습니다. 아데아 제약 솔루션, 아세지아 제약, 캐터런트, 론자, 루브리졸 생명과학 헬스, 페이스 생명과학 등 주요 기업이 이 분야에서 두각을 보이고 있습니다. 약 100개 기업이 의약품의 바이오 가용성 향상과 관련된 서비스 제공에 적극적으로 나서고 있으며, 이는 큰 경쟁을 유발하고 있습니다. 아웃소싱 모델의 부상으로 시장 성장이 가속화되고 있으며, 바이오베버리지 개선 원칙에 기반한 서비스 제공을 확대하는 중소기업이 증가하고 있습니다. 이러한 발전은 혁신과 전문 서비스가 제약업계 수요를 충족시키는 데 있으며, 핵심적인 역할을 하는 역동적인 산업 환경을 강조하고 있습니다.

최근 제온생명과학은 우수한 흡수율을 달성하고 생체이용률을 극대화하기 위해 액체로 채워진 캡슐을 출시했습니다. 이러한 잦은 기술 혁신으로 이 시장은 높은 경쟁력을 유지하고 있습니다.

목차

제1장 생체이용률 향상 기술 및 서비스 시장 개요

• 조사 범위
• 시장 추정년

제2장 개요

• 시장 내역
• 경쟁 인사이트

제3장 생체이용률 향상 기술 및 서비스 주요 시장 동향

• 시장 성장 촉진요인
• 시장 성장 억제요인
• 시장 기회
• 시장의 향후 동향

제4장 생체이용률 향상 기술 및 서비스 산업 연구

• PEST 분석
• Porter's Five Forces 분석
• 성장 전망 지도제작
• 규제 구조 분석

제5장 생체이용률 향상 기술 및 서비스 시장 : COVID-19 영향 분석

• COVID-19 이전 영향 분석
• COVID-19 이후 영향 분석

제6장 생체이용률 향상 기술 및 서비스 시장 구도

• 생체이용률 향상 기술 및 서비스 시장 점유율 분석, 2023년
• 주요 제조업체별 내역 데이터
  • 기존 기업 분석
  • 신규 기업 분석

제7장 생체이용률 향상 기술 및 서비스 시장 - 약제 유형별

• 개요
  • 부문 점유율 분석
  • 신약 승인
  • 제네릭

제8장 생체이용률 향상 기술 및 서비스 시장 - BCS 분류별

• 개요
  • 부문 점유율 분석
  • BCS II 클래스
  • BCS IV 클래스

제9장 생체이용률 향상 기술 및 서비스 시장 - 향상 접근별

• 개요
  • 부문 점유율 분석
  • 고체 분산
  • 사이즈 축소
  • 지질 기반 및 기타 접근

제10장 생체이용률 향상 기술 및 서비스 시장 - 제형별

• 개요
  • 부문 점유율 분석
  • 고체
  • 액체
  • 반고형물
  • 미립자

제11장 생체이용률 향상 기술 및 서비스 시장 - 지역별

• 서론
• 북미
  • 개요
  • 북미의 주요 제조업체
  • 미국
  • 캐나다
• 유럽
  • 개요
  • 유럽의 주요 제조업체
  • 독일
  • 이탈리아
  • 영국
  • 프랑스
  • 러시아
  • 네덜란드
  • 스웨덴
  • 폴란드
  • 기타
• 아시아태평양(APAC)
  • 개요
  • 아시아태평양의 주요 제조업체
  • 인도
  • 중국
  • 일본
  • 한국
  • 호주
  • 태국
  • 인도네시아
  • 필리핀
  • 기타
• 라틴아메리카
  • 개요
  • 라틴아메리카의 주요 제조업체
  • 브라질
  • 멕시코
  • 아르헨티나
  • 콜롬비아
  • 기타
• 중동 및 아프리카
  • 개요
  • 중동 및 아프리카의 주요 제조업체
  • 사우디아라비아
  • 아랍에미리트
  • 이스라엘
  • 터키
  • 알제리
  • 이집트
  • 기타

제12장 주요 벤더 분석 - 생체이용률 향상 기술 및 서비스업계

• 경쟁 대시보드
• 기업 개요
  • Lonza
  • Catalent
  • WuXi STA(A Subsidiary of WuXi AppTec)
  • Adare Pharma Solutions
  • Lubrizol Life Science Health
  • Pace Life Sciences
  • Quotient Sciences
  • Stapharma
  • AustinPx
  • BOC Sciences
  • Ascendia Pharmaceuticals

제13장 애널리스트의 전방위 전망

KSA

영문 목차

영문목차

REPORT HIGHLIGHT

Bioavailability Enhancement Technologies and Services Market size was valued at USD 2,123.45 Million in 2023, expanding at a CAGR of 7.5% from 2024 to 2032.

Bioavailability enhancement technologies play a pivotal role in pharmaceutical development by ensuring that drugs achieve optimal therapeutic effectiveness through improved absorption and distribution within the body. These technologies encompass a diverse range of approaches aimed at overcoming challenges such as poor solubility, limited permeability, and rapid metabolism of drug compounds. The aim is to maximize the therapeutic benefits of drugs by increasing their absorption rates and bioavailability. This can lead to more effective treatments with reduced dosage requirements, potentially lowering costs and minimizing adverse effects for patients.

Bioavailability Enhancement Technologies and Services Market- Market Dynamics

Chronic Disease Surge and Drug Development Challenges Propel Market Growth

The increasing prevalence of chronic diseases worldwide, coupled with the challenges faced in drug development, is driving significant growth in the market for bioavailability enhancement technologies and services. Recent data estimates by the World Heart Federation stated that over 20.5 million people died from CVDs, which is about one-third of all global deaths Chronic conditions such as cardiovascular diseases, diabetes, and cancer require effective therapies that can achieve optimal drug delivery and patient outcomes.

Bioavailability enhancement technologies play a crucial role in improving the absorption, solubility, and efficacy of drugs, thereby addressing these complex therapeutic needs. Pharmaceutical companies are increasingly investing in innovative formulation techniques and drug delivery systems to meet regulatory standards and enhance treatment options for chronic diseases, driving the expansion of this market segment.

Bioavailability Enhancement Technologies and Services Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.5% over the forecast period (2024-2032)

Based on Drug Type segmentation, New Drug Approvals were predicted to show maximum market share in the year 2023

Based on BCS Classification segmentation, BCS-II was the leading type in 2023

Based on Enhancement Approach segmentation, Solid Dispersion was the leading type in 2023

Based on the Dosage Form, Liquid was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Bioavailability Enhancement Technologies and Services Market- Segmentation Analysis:

The Global Bioavailability Enhancement Technologies and Services Market is segmented based on Drug Type, BCS Classification, Enhancement Approach, Dosage Form, and Region.

The market is divided into two categories based on Drug Type: New Drug Approvals and Generics. New drug approvals in bioavailability enhancement technologies and services indicate significant advancements in pharmaceutical formulation and delivery systems. These approvals often highlight innovative approaches to improving the absorption, solubility, and overall efficacy of drugs, particularly those with bioavailability challenges. Key trends in new approvals include the adoption of novel formulation techniques such as nanotechnology, lipid-based formulations, and controlled-release systems.

The market is divided into two categories based on BCS Classification: BCS II class and BCS IV class. BCS II Class has high permeability but low solubility. Enhancing the bioavailability of these drugs typically involves advanced formulation strategies such as particle size reduction, solid dispersion, cyclodextrin complexation, lipid-based formulations, and nanotechnology. These technologies aim to improve dissolution rates and ultimately enhance absorption, ensuring therapeutic efficacy.

Bioavailability Enhancement Technologies and Services Market- Geographical Insights

North America's dominance in the global market for drug bioavailability enhancement stems from its robust pharmaceutical industry, advanced regulatory environment, and strong research and development capabilities. The region hosts leading pharmaceutical companies with extensive research and manufacturing infrastructure dedicated to developing and implementing innovative technologies that enhance the absorption and effectiveness of drugs. Regulatory bodies, such as the FDA in the United States, enforce stringent standards for drug approval, including requirements for bioequivalence and therapeutic efficacy. This regulatory framework encourages continuous innovation in bioavailability enhancement technologies to meet rigorous criteria and ensure compliance, thereby driving market leadership.

Moreover, North America benefits from a dynamic ecosystem of academic and research institutions collaborating closely with industry stakeholders. This collaboration fosters the development of novel drug delivery systems, formulations, and biopharmaceuticals, contributing to advancements in bioavailability enhancement strategies.

Bioavailability Enhancement Technologies and Services Market- Competitive Landscape:

The market for drug bioavailability enhancement is fiercely competitive, featuring both small and large companies. Key players like Adare Pharma Solutions, Ascendia Pharmaceuticals, Catalent, Lonza, Lubrizol Life Science Health, and Pace Life Sciences are prominent in this field. Approximately 100 companies are actively engaged in providing services related to drug bioavailability enhancement, driving significant competition. The rise of outsourcing models has accelerated market growth, prompting smaller companies to expand their service offerings based on bioavailability enhancement principles. This evolution underscores a dynamic industry landscape where innovation and specialized services are key to meeting pharmaceutical industry demands.

Lately, Zeon Lifesciences launched liquid-filled capsules aimed at achieving superior absorption rates and maximizing bioavailability. Frequent innovations like these keep this market highly competitive.

Recent Developments:

In March 2023, The Gastrointestinal Simulator (GIS) outperformed the traditional United States Pharmacopoeia (USP) method in accurately predicting the in vivo performance of BCS Class IIA compounds. Enhancing the bioavailability of poorly soluble drugs necessitates a comprehensive grasp of the desired formulation, making accurate in vitro modeling of absorption mechanisms crucial.

In April 2024, AustinPx, a leading contract development and manufacturing organization (CDMO) focused on improving the bioavailability of orally delivered small molecule drug candidates, recently acquired a 3P Innovations API capsule filling machine, an FT4 Powder Rheometer, and the STYL'One Nano compaction simulator.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Lonza

Catalent

WuXi STA (A Subsidiary of WuXi AppTec)

Adare Pharma Solutions

Lubrizol Life Science Health

Pace Life Sciences

Quotient Sciences

Stapharma

AustinPx

BOC Sciences

Ascendia Pharmaceuticals

GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

• New Drug Approvals
• Generics

GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET, BY BCS CLASSIFICATION- MARKET ANALYSIS, 2019 - 2032

• BCS II Class
• BCS IV Class

GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET, BY ENHANCEMENT APPROACH- MARKET ANALYSIS, 2019 - 2032

• Solid Dispersion
• Size Reduction
• Lipid-based and other approaches

GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032

• Solids
• Liquids
• Semi-Solids
• Fine Particles

GLOBAL BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe
• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Bioavailability Enhancement Technologies and Services Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Bioavailability Enhancement Technologies and Services Market Snippet by Drug Type
  • 2.1.2. Bioavailability Enhancement Technologies and Services Market Snippet by BCS Classification
  • 2.1.3. Bioavailability Enhancement Technologies and Services Market Snippet by Enhancement Approach
  • 2.1.4. Bioavailability Enhancement Technologies and Services Market Snippet by Dosage Form
  • 2.1.5. Bioavailability Enhancement Technologies and Services Market Snippet by Country
  • 2.1.6. Bioavailability Enhancement Technologies and Services Market Snippet by Region
• 2.2. Competitive Insights

3. Bioavailability Enhancement Technologies and Services Key Market Trends

• 3.1. Bioavailability Enhancement Technologies and Services Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Bioavailability Enhancement Technologies and Services Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Bioavailability Enhancement Technologies and Services Market Opportunities
• 3.4. Bioavailability Enhancement Technologies and Services Market Future Trends

4. Bioavailability Enhancement Technologies and Services Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Bioavailability Enhancement Technologies and Services Market: COVID-19 Impact Analysis

• 5.1. Pre-COVID-19 Impact Analysis
• 5.2. Post-COVID-19 Impact Analysis
  • 5.2.1. Top Performing Segments
  • 5.2.2. Marginal Growth Segments
  • 5.2.3. Top Looser Segments
  • 5.2.4. Marginal Loss Segments

6. Bioavailability Enhancement Technologies and Services Market Landscape

• 6.1. Bioavailability Enhancement Technologies and Services Market Share Analysis, 2023
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Bioavailability Enhancement Technologies and Services Market - By Drug Type

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
  • 7.1.2. New Drug Approvals
  • 7.1.3. Generics

8. Bioavailability Enhancement Technologies and Services Market - By BCS Classification

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By BCS Classification, 2023 & 2032 (%)
  • 8.1.2. BCS II Class
  • 8.1.3. BCS IV Class

9. Bioavailability Enhancement Technologies and Services Market - By Enhancement Approach

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Enhancement Approach, 2023 & 2032 (%)
  • 9.1.2. Solid Dispersion
  • 9.1.3. Size Reduction
  • 9.1.4. Lipid-based and other approaches

10. Bioavailability Enhancement Technologies and Services Market - By Dosage Form

• 10.1. Overview
  • 10.1.1. Segment Share Analysis, By BCS Classification, 2023 & 2032 (%)
  • 10.1.2. Solids
  • 10.1.3. Liquids
  • 10.1.4. Semi-Solids
  • 10.1.5. Fine Particles

11. Bioavailability Enhancement Technologies and Services Market- By Geography

• 11.1. Introduction
  • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
• 11.2. North America
  • 11.2.1. Overview
  • 11.2.2. Bioavailability Enhancement Technologies and Services Key Manufacturers in North America
  • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  • 11.2.5. North America Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
  • 11.2.6. North America Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
  • 11.2.7. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.2.8. U.S.
    • 11.2.8.1. Overview
    • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.2.8.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.2.8.4. U.S. Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.2.8.5. U.S. Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.2.8.6. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.2.9. Canada
    • 11.2.9.1. Overview
    • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.2.9.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.2.9.4. Canada Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.2.9.5. Canada Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.2.9.6. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
• 11.3. Europe
  • 11.3.1. Overview
  • 11.3.2. Bioavailability Enhancement Technologies and Services Key Manufacturers in Europe
  • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  • 11.3.5. Europe Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
  • 11.3.6. Europe Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
  • 11.3.7. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.3.8. Germany
    • 11.3.8.1. Overview
    • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.8.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.8.4. Germany Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.3.8.5. Germany Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.3.8.6. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.3.9. Italy
    • 11.3.9.1. Overview
    • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.9.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.9.4. Italy Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.3.9.5. Italy Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.3.9.6. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.3.10. United Kingdom
    • 11.3.10.1. Overview
    • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.10.4. United Kingdom Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.3.10.5. United Kingdom Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.3.10.6. United Kingdom Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.3.11. France
    • 11.3.11.1. Overview
    • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.11.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.11.4. France Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.3.11.5. France Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.3.11.6. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.3.12. Russia
    • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.12.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.12.3. Russia Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.3.12.4. Russia Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.3.12.5. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.3.13. Netherlands
    • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.13.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.13.3. Netherlands Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.3.13.4. Netherlands Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.3.13.5. Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.3.14. Sweden
    • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.14.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.14.3. Sweden Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.3.14.4. Sweden Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.3.14.5. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.3.15. Poland
    • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.15.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.15.3. Poland Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.3.15.4. Poland Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.3.15.5. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.3.16. Rest of Europe
    • 11.3.16.1. Overview
    • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.16.4. Rest of the Europe Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.3.16.6. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
• 11.4. Asia Pacific (APAC)
  • 11.4.1. Overview
  • 11.4.2. Bioavailability Enhancement Technologies and Services Key Manufacturers in Asia Pacific
  • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  • 11.4.5. Asia Pacific Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
  • 11.4.6. Asia Pacific Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
  • 11.4.7. Asia Pacific Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.4.8. India
    • 11.4.8.1. Overview
    • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.8.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.8.4. India Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.4.8.5. India Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.4.8.6. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.4.9. China
    • 11.4.9.1. Overview
    • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.9.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.9.4. China Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.4.9.5. China Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.4.9.6. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.4.10. Japan
    • 11.4.10.1. Overview
    • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.10.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.10.4. Japan Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.4.10.5. Japan Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.4.10.6. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.4.11. South Korea
    • 11.4.11.1. Overview
    • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.11.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.11.4. South Korea Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.4.11.5. South Korea Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.4.11.6. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.4.12. Australia
    • 11.4.12.1. Overview
    • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.12.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.12.4. Australia Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.4.12.5. Australia Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.4.12.6. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.4.13. Thailand
    • 11.4.13.1. Overview
    • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.13.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.13.4. Thailand Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.4.13.5. Thailand Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.4.13.6. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.4.14. Indonesia
    • 11.4.14.1. Overview
    • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.14.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.14.4. Indonesia Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.4.14.5. Indonesia Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.4.14.6. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.4.15. Philippines
    • 11.4.15.1. Overview
    • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.15.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.15.4. Philippines Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.4.15.5. Philippines Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.4.15.6. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.4.16. Rest of APAC
    • 11.4.16.1. Overview
    • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.16.4. Rest of APAC Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.4.16.5. Rest of APAC Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.4.16.6. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
• 11.5. Latin America
  • 11.5.1. Overview
  • 11.5.2. Bioavailability Enhancement Technologies and Services Key Manufacturers in Latin America
  • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  • 11.5.5. Latin America Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
  • 11.5.6. Latin America Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
  • 11.5.7. Latin America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.5.8. Brazil
    • 11.5.8.1. Overview
    • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.8.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.5.8.4. Brazil Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.5.8.5. Brazil Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.5.8.6. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.5.9. Mexico
    • 11.5.9.1. Overview
    • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.9.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.5.9.4. Mexico Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.5.9.5. Mexico Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.5.9.6. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.5.10. Argentina
    • 11.5.10.1. Overview
    • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.10.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.5.10.4. Argentina Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.5.10.5. Argentina Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.5.10.6. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.5.11. Colombia
    • 11.5.11.1. Overview
    • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.11.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.5.11.4. Colombia Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.5.11.5. Colombia Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.5.11.6. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.5.12. Rest of LATAM
    • 11.5.12.1. Overview
    • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.5.12.4. Rest of LATAM Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
• 11.6. Middle East and Africa
  • 11.6.1. Overview
  • 11.6.2. Bioavailability Enhancement Technologies and Services Key Manufacturers in Middle East and Africa
  • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  • 11.6.5. Middle East and Africa Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
  • 11.6.6. Middle East and Africa Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
  • 11.6.7. Middle East and Africa Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.6.8. Saudi Arabia
    • 11.6.8.1. Overview
    • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.8.4. Saudi Arabia Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.6.9. United Arab Emirates
    • 11.6.9.1. Overview
    • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.9.4. United Arab Emirates Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.6.10. Israel
    • 11.6.10.1. Overview
    • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.10.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.10.4. Israel Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.6.10.5. Israel Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.6.10.6. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.6.11. Turkey
    • 11.6.11.1. Overview
    • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.11.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.11.4. Turkey Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.6.11.5. Turkey Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.6.11.6. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.6.12. Algeria
    • 11.6.12.1. Overview
    • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.12.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.12.4. Algeria Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.6.12.5. Algeria Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.6.12.6. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.6.13. Egypt
    • 11.6.13.1. Overview
    • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.13.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.13.4. Egypt Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.6.13.5. Egypt Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.6.13.6. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  • 11.6.14. Rest of MEA
    • 11.6.14.1. Overview
    • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.14.4. Rest of MEA Market Size and Forecast, By BCS Classification, 2019 - 2032 (US$ Million)
    • 11.6.14.5. Rest of MEA Market Size and Forecast, By Enhancement Approach, 2019 - 2032 (US$ Million)
    • 11.6.14.6. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Bioavailability Enhancement Technologies and Services Industry

• 12.1. Competitive Dashboard
• 12.2. Company Profiles
  • 12.2.1. Lonza
  • 12.2.2. Catalent
  • 12.2.3. WuXi STA (A Subsidiary of WuXi AppTec)
  • 12.2.4. Adare Pharma Solutions
  • 12.2.5. Lubrizol Life Science Health
  • 12.2.6. Pace Life Sciences
  • 12.2.7. Quotient Sciences
  • 12.2.8. Stapharma
  • 12.2.9. AustinPx
  • 12.2.10. BOC Sciences
  • 12.2.11. Ascendia Pharmaceuticals

13. 360 Degree Analyst View

14. Appendix

• 14.1. Research Methodology
• 14.2. References
• 14.3. Abbreviations
• 14.4. Disclaimer
• 14.5. Contact Us

관련자료